These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 25077372)

  • 1. Prospects and perspectives for development of a vaccine against herpes simplex virus infections.
    McAllister SC; Schleiss MR
    Expert Rev Vaccines; 2014 Nov; 13(11):1349-60. PubMed ID: 25077372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of herpes simplex virus infection and pathogenesis suggest a strategy for vaccine development.
    Xu X; Zhang Y; Li Q
    Rev Med Virol; 2019 Jul; 29(4):e2054. PubMed ID: 31197909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus.
    Ferenczy MW
    Curr Pharm Des; 2007; 13(19):1975-88. PubMed ID: 17627531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Herpes simplex virus vaccines: perspectives].
    Deback C; Huraux JM
    Rev Med Interne; 2007 Jan; 28(1):16-21. PubMed ID: 17095125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Varicella zoster vaccines and their implications for development of HSV vaccines.
    Gershon AA
    Virology; 2013 Jan; 435(1):29-36. PubMed ID: 23217613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ongoing pursuit of a prophylactic HSV vaccine.
    Chung E; Sen J
    Rev Med Virol; 2012 Sep; 22(5):285-300. PubMed ID: 22396215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Herpes simplex virus vaccine studies: from past to present].
    Us D
    Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond.
    Chang JY; Balch C; Oh HS
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for control of herpes simplex virus disease through immunization.
    Stanberry LR; Cunningham AL; Mindel A; Scott LL; Spruance SL; Aoki FY; Lacey CJ
    Clin Infect Dis; 2000 Mar; 30(3):549-66. PubMed ID: 10722443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcutaneous immunisation with herpes simplex virus stimulates immunity in mice.
    El-Ghorr AA; Williams RM; Heap C; Norval M
    FEMS Immunol Med Microbiol; 2000 Dec; 29(4):255-61. PubMed ID: 11118905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heat-shock protein 70 acts as an effective adjuvant in neonatal mice and confers protection against challenge with herpes simplex virus.
    Pack CD; Kumaraguru U; Suvas S; Rouse BT
    Vaccine; 2005 May; 23(27):3526-34. PubMed ID: 15855011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of DNA encoding cytokines on systemic and mucosal immunity following genetic vaccination against herpes simplex virus.
    Lee S; Gierynska M; Eo SK; Kuklin N; Rouse BT
    Microbes Infect; 2003 Jun; 5(7):571-8. PubMed ID: 12787733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.
    Stanfield BA; Stahl J; Chouljenko VN; Subramanian R; Charles AS; Saied AA; Walker JD; Kousoulas KG
    PLoS One; 2014; 9(10):e109890. PubMed ID: 25350288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity.
    Lauterbach H; Ried C; Epstein AL; Marconi P; Brocker T
    J Gen Virol; 2005 Sep; 86(Pt 9):2401-2410. PubMed ID: 16099897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSV-2 vaccine: current status and insight into factors for developing an efficient vaccine.
    Zhu XP; Muhammad ZS; Wang JG; Lin W; Guo SK; Zhang W
    Viruses; 2014 Jan; 6(2):371-90. PubMed ID: 24469503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential impact of a prophylactic herpes simplex vaccine.
    Rupp R; Bernstein DI
    Expert Opin Emerg Drugs; 2008 Mar; 13(1):41-52. PubMed ID: 18321147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of local PD-1+ TIM-3+ CD8+ exhausted T cells.
    Khan AA; Srivastava R; Chentoufi AA; Geertsema R; Thai NT; Dasgupta G; Osorio N; Kalantari M; Nesburn AB; Wechsler SL; BenMohamed L
    J Virol; 2015 Jul; 89(13):6619-32. PubMed ID: 25878105
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107
    Khan AA; Srivastava R; Vahed H; Roy S; Walia SS; Kim GJ; Fouladi MA; Yamada T; Ly VT; Lam C; Lou A; Nguyen V; Boldbaatar U; Geertsema R; Fraser NW; BenMohamed L
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29899087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estradiol Enhances Antiviral CD4
    Bagri P; Ghasemi R; McGrath JJC; Thayaparan D; Yu E; Brooks AG; Stämpfli MR; Kaushic C
    J Virol; 2020 Dec; 95(1):. PubMed ID: 33028712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.